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Abstract
Galectin-3 is a b-galactoside binding lectin with roles in diverse processes including proliferation, apoptosis, inflammation
and fibrosis which are dependent on different domains of the molecule and subcellular distribution. Although galectin-3 is
known to be upregulated in acute kidney injury, the relative importance of its different domains and functions are poorly
understood in the underlying pathogenesis. Therefore we experimentally modulated galectin-3 in folic acid (FA)-induced
acute kidney injury utilising modified citrus pectin (MCP), a derivative of pectin which can bind to the galectin-3
carbohydrate recognition domain thereby predominantly antagonising functions linked to this role. Mice were pre-treated
with normal or 1% MCP-supplemented drinking water one week before FA injection. During the initial injury phase, all FA-
treated mice lost weight whilst their kidneys enlarged secondary to the renal insult; these gross changes were significantly
lessened in the MCP group but this was not associated with significant changes in galectin-3 expression. At a histological
level, MCP clearly reduced renal cell proliferation but did not affect apoptosis. Later, during the recovery phase at two
weeks, MCP-treated mice demonstrated reduced galectin-3 in association with decreased renal fibrosis, macrophages, pro-
inflammatory cytokine expression and apoptosis. Other renal galectins, galectin-1 and -9, were unchanged. Our data
indicates that MCP is protective in experimental nephropathy with modulation of early proliferation and later galectin-3
expression, apoptosis and fibrosis. This raises the possibility that MCP may be a novel strategy to reduce renal injury in the
long term, perhaps via carbohydrate binding-related functions of galectin-3.
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Introduction
Galectins are low molecular weight, calcium-independent, b-
galactoside-binding lectins [1]. Galectin-3 is a multi-domain
molecule which includes an N-terminal proline-rich domain and
a C-terminal carbohydrate recognition domain essential for
binding simple b-galactosides such as lactosamine and Galb1-
4GlcNAc; and for higher affinity binding to polylactosamine
chains [2]. Galectin-3 plays a key role in several intracellular
physiological and pathological processes including proliferation
and apoptosis, via carbohydrate-independent mechanisms [3–5].
In addition, galectin-3 is involved in modulation of cell-cell
interactions and inflammation, predominately through extracellu-
lar carbohydrate binding functions [6–9]. In the kidney, galectin-3
is strongly expressed in the ureteric bud and its derivatives, the
collecting ducts, in normal development and the mature organ
[8,10]. Lower levels are also sometimes observed in mature tubules
[11] but the lectin is expressed in a more widespread distribution
in models of acute kidney damage such as ischemia-reperfusion
injury or high-dose folic acid (FA) treatment [12]. In this latter
model, FA initially undergoes glomerular filtration following
systemic injection, and precipitates in the tubules which become
damaged with a loss of epithelial cell integrity due to necrosis and
apoptosis [13,14]. After two days, the majority of the tubules show
regenerative changes as new cells proliferate and migrate to repair
the denuded areas of the tubule [15]. However, over the next two
weeks there is incomplete healing in some areas of the kidney, as
evidenced by patchy interstitial fibrosis, loss of peritubular
capillaries and inflammation with macrophage infiltration
[16,17]. In the FA model, galectin-3 expression is initially observed
in both proximal and distal tubules, and thick ascending limbs as
well as collecting ducts; later, it is detectable in macrophages,
particularly in areas of inflammation [12]. Several lines of
evidence suggest that galectin-3 is beneficial in experimental
kidney diseases such as polycystic kidney disease [18], nephrotoxic
nephritis [19] and unilateral ureteric obstruction (UUO) [11], but
its functional importance in FA-induced acute kidney injury is
unknown. Therefore, we utilised this model and modulated
galectin-3 levels using modified citrus pectin (MCP), a derivative
of pectin; which is a soluble dietary fibre found in the peel and
pulp of citrus fruits [20]. MCP contains fragments of the original
pectin molecule, including rhamnogalacturonan 1 regions which
contain galactan side-chains [21] which bind to the carbohydrate
recognition domain of galectin-3 [22,23], hence modulating
galectin-3 bioactivity by altering extracellular functions such as
cell-cell interactions and inflammation.
Methods
Experimental Strategy
Reagents were obtained from Sigma Chemical Company
(Poole, UK) unless otherwise stated. Eight week-old male C57Bl/
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6J mice (Charles River Laboratories, Margate, UK), of average
weight 25 g were used in procedures approved by the UCL local
ethics committee and the UK Home Office (project licence PPL
70/6627). The three main experimental groups are depicted in
Figure 1. Group I (n = 8), the ‘sham controls’, were provided with
normal drinking water ad libitium throughout, injected with
intraperitoneal (IP) sodium bicarbonate (NaHCO3, 0.2 ml,
0.3 M; the vehicle used for FA administration) at Day 0; and
were killed either at Day 2 (n = 4) or Day 14 (n = 4). Groups II
and III were used to induce FA-nephropathy. Group II (n = 14),
were also provided with normal drinking water throughout but
were injected on Day 0 with 240 mg/g body weight FA, a dose
which reliably caused ‘acute tubular necrosis’ in all mice, with a
low mortality rate (less than 5%) over 14 days observation
[16,17]. Group III (n = 14), were administered 1% MCP
(Pectasol, EcoNugenics, Santa Rosa, CA) in the drinking water
for seven days before the IP FA and then continued on MCP
throughout the protocol. This dose of MCP previously led to
effective galectin-3 blockade and was non-toxic in murine cancer
studies examining parameters such as tumour growth, angiogen-
esis and spontaneous metastasis [24]. Lower doses of MCP also
prevent galectin-3 mediated functions in-vitro including chemo-
taxis and cell adhesion [24,25], but there is no data showing this
would be replicated in-vivo. Experiments were also performed to
ensure that pectin itself did not have adverse effects. In both
Groups II and III, one mouse died spontaneously at Day 1 and
the remainder were killed at either Day 2 or Day 14 of the
protocol. All of the assessments were made blinded to
experimental groups.
Histology and Blood Analyses
Body and kidney weights were measured and right-sided
kidneys used for histology and left-sided kidneys for biochem-
ical studies. Blood was collected by exsanguination and
commercially available assay kits, validated in mice, were used
to assess creatinine (Cusabio, Newark, Delaware) and blood
urea nitrogen (BUN) (BioAssay Systems, Hayward, CA).
Kidneys were fixed in 4% paraformaldehyde, embedded in
wax, then five mm sections were cut, dewaxed and rehydrated
for immunohistochemistry as described [17] for primary
antibodies: rabbit anti-human galectin-3 (Santa Cruz Biotech-
nology, Santa Cruz, CA); rat anti-mouse macrophage marker
(F4/80; Serotec, Raleigh, NC), rat anti-mouse neutrophil
(MCA771G; Serotec), goat anti-human collagen I (Southern
Biotech, Birmingham, AL), goat anti-human collagen III
(Southern Biotech), and mouse anti-human proliferating cell
nuclear antigen (PCNA, BD Biosciences, Oxford, UK).
Negative controls consisted of omission of primary antibodies
or substitution with preimmune serum. Some sections were
stained with either periodic acid Schiff reagent (PAS) and/or
haematoxylin. For collagen I, collagen III, and macrophage
staining photomicrographs of 20 sequential fields using an620
Figure 1. Experimental groups I-III.
doi:10.1371/journal.pone.0018683.g001
Figure 2. Galectin-3 expression in FA nephropathy. A. Sham control kidneys contained positive galectin-3 expression primarily in collecting
ducts. B. Two days after FA administration, prominent galectin-3 expression was observed in dilated tubules (indicated by *, g = glomerulus). This
was maintained in the recovery phase of FA nephropathy after 14 days, but in addition positive galectin-3 was observed in infiltrating cells in fibrotic
areas (arrows, C). Bars are 50 mm.
doi:10.1371/journal.pone.0018683.g002
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objective were taken and the area of the kidney cortex
containing positive immuno-reactivity was analysed as a
percentage of the whole image using Image J software
(http://rsbweb.nih.gov.ij/) [16]. The number of positive
galectin-3 interstitial cells was also determined in 20 random
fields from the renal cortex using620 objective. For PCNA and
neutrophil staining, the numbers of positive cells were counted
in both 20 random fields from the renal cortex and 50 glomeruli
for each kidney using 620 and 640 objectives respectively.
Detection of apoptosis was performed by TUNEL staining as
previously described [26]. For each kidney, the numbers of
positive cells were counted in both 20 random fields from the
renal cortex and 50 sequential glomeruli.
Real-Time Polymerase Chain Reaction (RT-PCR)
RNA was extracted using the RNeasy kit (Qiagen, Crawley,
West Sussex, UK) from whole kidneys of animals and 500 ng
used to prepare cDNA. Quantitative RT-PCR was performed
for both fibrotic genes (a-smooth muscle actin (a-SMA),
collagen I, collagen III, fibronectin, galectin-1, galectin-3,
galectin-9 and transforming growth factor b1 (TGFb1)) and
cytokines (interleukin-1b (IL-1b), interleukin-6 (IL-6), mono-
cyte chemoattractant protein-1 (MCP-1) and tumour necrosis
factor-a (TNF-a)) using previously described methods [27]
with hypoxanthine-guanine phosphoribosyltransferase (HPRT)
as a house-keeping gene. Primer details are available on
request.
Western blotting
Western blotting was performed on 100 mg of protein prepared
from whole kidney tissue as previously described [17]. Blots were
incubated with rabbit anti-human galectin-3 antibody (Santa Cruz
Biotechnology) and bands detected by chemiluminescence. Blots
were stripped and then reprobed for GAPDH (Abcam, Cam-
bridge, UK) as a housekeeping gene. Band intensity was measured
by densitometry.
Figure 3. Effect of MCP on galectin expression in FA nephropathy. Quantitative RT-PCR for renal galectin-3 (A), galectin-1 (B) and galectin-9
(C) on kidney RNA from animals in Group I (water throughout, NaHCO3 injection), Group II (water throughout, FA injection) and Group III (MCP
throughout and FA injection), two and fourteen days after FA administration (n = 4 in Group I, 6–7 at each time-point in Group II and Group III). All
galectins were significantly upregulated in FA-treated animals at both time-points, but MCP only diminished galectin-3 levels fourteen days after
induction of FA nephropathy. (D) Western blotting for galectin-3 in kidney samples from Groups II and III collected 14 days after induction of FA
nephropathy. Following densitometry analysis (n = 6–7 in each group), galectin-3 protein levels were shown to be significantly decreased in FA
animals administered MCP. ** indicates p,0.01 between Groups while * indicates p,0.05 between Groups.
doi:10.1371/journal.pone.0018683.g003
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Statistics
Data were presented as means 6 standard error of the mean
(SEM). Differences in the various parameters between groups were
evaluated by Mann-Whitney U-test (SPSS, Chicago, IL). Statistical
significance was accepted at p,0.05.
Results
Galectin-3 expression is more widespread in FA
nephropathy
Sham control kidneys contained positive galectin-3 expression
in collecting ducts (Figure 2A). Two days after FA administration,
widespread galectin-3 expression was observed in diverse subsets
of tubules including dilated proximal tubules as well as collecting
ducts (Figure 2B). This expanded distribution was maintained in
the recovery phase of FA nephropathy after 14 days and in
addition galectin-3 positive cells were observed in fibrotic areas
consistent with macrophage localisation (Figure 2C).
MCP administration reduces galectin-3 upregulation in
the recovery phase of FA nephropathy
To assess the effect of MCP on galectin-3 levels, we used
quantitative RT-PCR and Western blotting. In agreement with
our immunostaining observations, kidneys of FA-exposed
animals (Group II) contained significantly higher galectin-3
mRNA levels than sham controls (Group I) at both experimental
day 2 and 14 (Figure 3A). Administration of MCP (Group III)
did not significantly alter galectin-3 mRNA levels at 2 days but
there was a statistically significant reduction at day 14
(Figure 3A). This reduction was confirmed at the protein level
at day 14: a galectin-3 doublet was detected at the expected size
of around 30 kDa which was significantly decreased in FA-
animals administered MCP (Figure 3D). At this time-point the
number of galectin-3 positive interstitial cells was also signifi-
cantly decreased in MCP FA-treated mice compared to FA-
animals drinking normal water (13.661.2 versus 23.863.1
positive interstitial cells/field respectively, p,0.01). Since
galectin-1 and galectin-9 are also expressed in the kidney and
might potentially substitute for some of the roles of galectin-3,
we also assessed their mRNA levels following FA and pectin.
Both galectin-1 and galectin-9 mRNA levels were upregulated
in FA animals compared to sham controls in both the acute and
recovery phases, but these increases were not significantly
altered by MCP (Figure 3B–C).
MCP administration reduces proliferation in the acute
phase of FA nephropathy
All mice treated with FA became unwell and developed acute
renal injury within two days, with increases in serum creatinine of
7–8 fold and in BUN of 9–10 fold (Table 1). FA animals drinking
normal water lost just under 10% of their body weight and had
significantly enlarged kidneys compared to sham controls (Figure 4,
Table 1). Histological examination revealed acute kidney damage
in all animals administered FA, with flattened proximal and distal
tubule epithelia and casts in tubule lumens (Figure 5A–C). There
was also increased cell proliferation as evidenced by more frequent
mitotic figures and significantly elevated numbers of cells
expressing the proliferation marker PCNA when compared to
sham controls (Figure 5D–F, Table 2). There were also more
apoptotic cells (Table 2). There were virtually no proliferating or
apoptotic cells observed in the glomeruli in any of the
experimental groups, confirming our prior studies that FA
primarily induces tubular damage [16,17]. We also assessed the
expression of the fibrosis-associated genes collagen I and III using
quantitative immunohistochemistry: both collagens were signifi-
cantly upregulated in the kidneys of FA-exposed animals versus
sham controls. Unsurprisingly, since there is little macrophage
infiltration at this stage of the disease [17], we did not observe any
changes in the area of the kidney containing F4/80 positive cells
between FA-exposed and sham control animals (Table 2).
FA also caused severely impaired kidney function in MCP-
maintained mice, with increases in serum creatinine and BUN
comparable to those given normal drinking water. Clinically,
however, the MCP mice had reduced severity of disease: they
had preserved body weight (mean 23.6 g), which is similar to
sham controls (Figure 4, Table 1), whilst kidney weights (0.16 g)
were higher than shams but significantly reduced compared to
those exposed to FA but maintained on water alone (Figure 4,
Table 1). Histologically, MCP administration significantly
reduced the number of proliferating cells in FA-treated animals
(water/FA 17.963.3; MCP/FA 7.262.8) but did not signifi-
cantly alter levels of apoptosis (water/FA 2.760.6, MCP/FA
1.860.6). MCP administration did not alter collagen I or III
expression (Table 2).
MCP reduces fibrosis and apoptosis after 14 days.
Mice are in the recovery phase by day 14, and we observed
body and kidney weight similar to sham values in both water and
MCP-maintained animals (Figure 4, Table 1). The whole of the
Table 1. Kidney weights and renal excretory function.
Group I
H20cNaHCO3
Group II
H20cFA
Group III
MCPcFA
(n=8) Day 2 (n =7) Day 14 (n =6) Day 2 (n =6) Day 14 (n=7)
Body weight (g) 23.860.4 21.660.4a 23.160.9 23.660.7d 22.462.0
Kidney weight (g) 0.1360.01 0.1960.01a 0.1260.01c 0.1660.01a,d,e 0.1160.01c,f
Kidney/body weight
(x100)
0.5560.03 0.8760.04a 0.5060.02c 0.6960.05b,d,e 0.5260.03c,f
Serum creatinine
(mM)
2261 147615 a 4061a,c 15768a,e 3762a,c,f
BUN (mM) 761 72617a 1862a,c 6264a,e 1661a,c,f
Modified citrus pectin (MCP) or normal drinking water was administered seven days prior to the injection of either FA or vehicle only (NaHCO3) at Day 0. All data are
given as mean6 SEM. a = p,0.01 compared to Group I, b = p,0.05 compared to Group I, c = p,0.01 compared to Group II at day 2, d =p,0.05 compared to Group II
at day 2, e = p,0.01 compared to Group II at day 14, f = p,0.01 compared to Group III at day 2.
doi:10.1371/journal.pone.0018683.t001
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kidney does not return to normal, however, and depressed areas
on the kidney surface were detectable in all FA animals, indicating
underlying tissue fibrosis. Blood creatinine and BUN levels
improved from the acute phase; but both remained significantly
increased compared to sham controls (Table 1; creatinine elevated
1.7–1.9 fold; BUN up 2.1–2.3x). Levels were marginally higher in
those drinking normal rather than MCP-supplemented water, but
this was not statistically significant (Table 1).
Histologically, in non-fibrotic areas, most of the cortex appeared
normal by 2 weeks after the FA. More cells positive for PCNA
were still observed (Table 2) than sham controls but there was no
difference between animals drinking unsupplemented and 1%
MCP water. Levels of apoptosis were greater than during the acute
phase, suggestive of remodeling and deletion of unwanted cells
from the regenerative stage. There was a striking difference
between the water and MCP-maintained groups, with much more
apoptosis in the former (p,0.01, Table 2). In fibrotic areas,
collagen I and III deposition and infiltration of inflammatory cells
were clearly visible using immunohistochemistry (Figure 6,
Table 2); intriguingly, collagen I staining and numbers of
macrophages were significantly reduced in the MCP group, but
collagen III and numbers of neutrophils in the interstitium
(9.662.5 and 7.361.4 cells/field in FA-animals drinking normal
and MCP water respectively) were unchanged.
We sought quantification by real-time RT-PCR of the collagens
and other fibrotic markers including a-SMA, fibronectin, and
TGFb1. There were increased levels of all of these genes in the
kidneys of FA-exposed animals compared to sham controls
(Figure 7A–E). MCP caused significant attenuation of the
increases for most of these fibrotic markers (a-SMA p,0.01;
collagen I, fibronectin and TGFb1 p,0.05); but again did not
alter collagen III (p = 0.18). We also examined a selection of
cytokines previously shown to be involved in the inflammatory
responses in acute kidney disease [28]. FA-exposed kidneys
contained elevated levels of the cytokines IL-1b, IL-6, MCP-1,
and TNF-a compared to sham controls (Figure 7F–I). MCP led to
significantly decreased levels of IL-1b and TNF-a, p,0.05); MCP-
1 and IL-6 were both lower but this did not reach statistical
significance.
MCP has no effects in normal healthy animals
One potential explanation for the MCP-associated benefits
could be that pectin simply makes the mice drink more, thus they
are better hydrated at the time of FA-induced injury and suffer less
renal consequences. To address this, we also assessed whether
MCP has any effects on mice injected with vehicle (sodium
bicarbonate): animals were given water supplemented with MCP
for 7 days, then injected with sodium bicarbonate and continued
on MCP before analysis two weeks later and compared to Group I.
Administration of MCP did not alter water intake, body or kidney
weight, renal function, or induce any changes in renal histology as
assessed by fibrotic, inflammatory and proliferative markers (data
not shown).
Figure 4. Assessment of kidney and body weights. Body (A),
kidney (B) and kidney/body weights (C) were assessed in Group I
(normal water throughout, injected with vehicle NaHCO3 as sham
control), Group II (normal water throughout, injected with FA) and
Group III (normal water supplemented with 1% MCP for 7 days prior to
injection with FA, and continued thereafter). Two days after FA, animals
drinking normal water had elevated kidney weights, increased kidney/
body weights and decreased body weights compared to sham controls.
MCP administration prevented the loss in body weight at this time-
point with levels similar to sham controls. Kidney weights and kidney/
body weights in MCP FA-exposed animals two days after FA exposure
remained higher than sham controls but were significantly reduced
compared to FA animals drinking normal water. By Day 14 of the
protocol, the initial swelling in FA-exposed kidneys subsided, with
kidney, body and kidney/body weight ratios returning to those
observed in sham controls; administration of MCP did not alter
kidney/body weight ratios at this time-point. ** indicates p,0.01
between Groups while * indicates p,0.05 between Groups.
doi:10.1371/journal.pone.0018683.g004
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Discussion
In our study, we investigated roles of galectin-3 in the FA
model of acute kidney injury using the natural inhibitor MCP.
Our principal findings were that MCP reduced acute renal
enlargement and proliferative responses in the initial phases of FA
nephropathy, then decreased renal apoptosis, inflammation and
fibrosis in the later phase. MCP did not alter galectin-3 initially,
but the latter effects were associated with significantly decreased
galectin-3 levels, with no change in other renal galectins. This
data raises the possibility that modulation of galectin-3 may be a
novel strategy to reduce acute renal injury. Indeed, Fernandes
Bertocchi and colleagues [29] demonstrated acute kidney damage
induced by ischemia reperfusion was attenuated in mice lacking
galectin-3 with an improvement in blood urea nitrogen 6 and
24 hours after the initial insult, but no difference at later time-
points. Structurally, the knock-out animals presented with less
acute tubular necrosis and a more prominent tubular regener-
ation when compared with controls and an improvement in
inflammation [29].
MCP is a derivative of pectin; a soluble dietary fibre found in
the peel and pulp of citrus fruits [20], and has inhibitory effects on
the progression of several animal models of cancer [24,30]. MCP
is rich in b-galactoside residues and binds to the carbohydrate
recognition domain of galectin-3 [22,23] thereby impairing the
lectin’s carbohydrate binding-related functions. Therefore, it could
be postulated that if MCP acted only through galectin-3 in FA
nephropathy it would not have any effect on intracellular actions
including proliferation and apoptosis, while modulating extracel-
lular functions such as inflammation. This proved not the case;
MCP treatment reduced tubular proliferation two days following
FA administration with no differences in galectin-3 expression.
Figure 5. Kidney histology two days after FA exposure. A–C. PAS staining on a representative sham control and FA kidneys after 2 days.
Marked kidney damage was noted in all animals administered FA, with flattened proximal and distal tubule epithelia with casts in tubule lumens
(indicated by *, g = glomerulus). There was no observed difference between FA animals administered normal drinking water (B) or those
supplemented with 1% modified citrus pectin (C). D–F. Assessment of proliferation by PCNA immunostaining. D. Occasional positive cells (brown
signal, arrows indicate some of these positive cells) were observed in sham controls. E. Kidneys of animals injected with FA showed markedly
increased numbers of PCNA positive cells predominately in tubular epithelium. Kidneys from FA animals provided with MCP in the drinking water had
significantly decreased numbers of PCNA positive cells (F, p,0.05). Bars are 50 mm.
doi:10.1371/journal.pone.0018683.g005
Table 2. Histological parameters.
Group I
H20cNaHCO3
Group II
H20cFA
Group III
MCPcFA
(n=8) Day 2 (n =7) Day 14 (n=6) Day 2 (n=6) Day 14 (n =7)
Proliferating cells (number per
field)
0.960.3 17.963.3a 3.860.4a,b 7.262.8a,c 5.161.3a,b
Apoptotic cells (number per
fields)
0.760.1 2.760.6a 4.361.4a,b 1.860.6a,d 2.860.2a,d
Collagen I area (%) 0.560.1 2.560.7a 1.360.2a 2.360.4a 0.560.1b,e,f
Collagen III area (%) 1.260.1 3.060.3a 2.660.3a 2.260.2a 2.260.3b
Macrophage area (%) 0.460.1 0.260.1a 6.561.0b 0.360.1d 3.860.5a,b,e,f
Modified citrus pectin (MCP) or normal drinking water was administered seven days prior to the injection of either FA or vehicle only (NaHCO3) at Day 0. All data are
given as mean6 SEM. a = p,0.01 compared to Group I; b = p,0.01 compared to Group II data at Day 2; c = p,0.05 compared to Group II data at day 2; d = p,0.01
compared to Group II data at Day 14; e = p,0.05 compared to Group II data at Day 14; f = p,0.01 compared to Group III data at Day 2.
doi:10.1371/journal.pone.0018683.t002
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Most studies have only considered the effects of MCP in relation to
galectin-3, but many other pathways could modulate proliferation
here, such as MAP kinase activation [31]. One could speculate
that an alternative explanation is that it is not just galectin-3 levels
but also bioavailability that should be considered. It is possible that
similar levels of galectin-3 have less biological effects when MCP is
present because its carbohydrate binding roles will be abrogated.
This cannot be measured in-vivo at present, but in-vitro studies
have shown that both cell migration [24] and agglutination [32]
are diminished in the presence of MCP when induced with similar
concentrations of galectin-3. The reduced proliferation could also
suggest renal recovery is slower in MCP-treated mice or
alternatively that MCP may protect the kidney against structural
injury. This second explanation is supported by the fact MCP mice
have preserved body weight and their kidneys did not exhibit such
acute gross swelling as those exposed to FA but maintained on
water alone.
MCP decreased renal mRNA and protein levels of galectin-3 at
14 days after FA injection, in concert with significantly improved
renal fibrosis as assessed by reduced expression of multiple fibrotic
genes. MCP had no effect on galectin-1 and galectin-9, which are
also expressed in the kidney [33,34], suggesting these effects do not
result from MCP interactions with other galectins. The direct
correlation of less galectin-3 with less renal injury is consistent with
studies by Henderson and colleagues [35] wherein mice lacking
galectin-3 have less fibrosis and decreased collagen and a-SMA
expression seven days after UUO. In contrast, a recent paper
reported that fibrosis severity was increased by day 14 post UUO
in galectin-3 deficient mice [11]. These observations may not
relate directly to our model, however, because the pathology of
chronic UUO is very different to FA-induced injury and both of
these studies focussed on knock-out mice where both carbohydrate
binding-dependent and -independent functions are abrogated.
The growth factor TGF-b plays a key role in the progression of
renal fibrosis by promoting myofibroblastic differentiation [36]
and galectin-3 has been implicated in this type of differentiation
and extracellular matrix production in hepatic stellate cells [37].
MCP reduced TGF-b mRNA here, which may have contributed
to reduced myofibroblast formation as evidenced by decreased a-
SMA levels. An unexpected finding was the lack of significant
differences in collagen III expression with MCP, which contrasts
with the other profibrotic factors examined. A correlation between
galectin-3 and collagen I, but not with collagen III, was recently
reported by Okamura and colleagues [11]: they noted that lack of
galectin-3 led to a relative fall in collagen I but not III over time in
UUO. Sharma et al. also observed differential effects of galectin-3
on different collagens [38]: they initially found that galectin-3 was
strongly upregulated in an animal model of heart failure, and then
infused galectin-3 into the pericardial sac of healthy rats to induce
left ventricular dysfunction; this led to a 3-fold increase of collagen
I over collagen III. A potential mechanism may be that the
collagen I promoter, contains a high number of Sp-1 binding sites
[39] through which galectin-3 might act [3] but these are not
present for collagen III.
MCP also reduced inflammatory responses at day 14 of FA
nephropathy which was accompanied by a loss of galectin-3
Figure 6. Histological observations fourteen days after FA nephropathy. Immunohistochemistry with collagen I (A–C) and III (D–F)
demonstrated patchy fibrotic areas 14 days following FA administration (brown signals, g = glomerulus) and quantification revealed a marked
increase compared to sham controls. Collagen I staining, but not collagen III was reduced in FA-animals administered MCP in their drinking water
compared to those drinking normal water. The area of the kidney containing macrophages was increased in animals exposed to FA versus sham
controls as assessed by F4/80 staining (G–I) and this increase was attenuated in MCP FA mice. Bars are 50 mm in A–F and 100 mm in G–I.
doi:10.1371/journal.pone.0018683.g006
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positive interstitial cells in the kidney. Galectin-3 is upregulated in
several other renal diseases with prominent inflammatory
components including systemic lupus erythematosus [40], exper-
imental glomerulonephritis [41] and unilateral ureteral obstruc-
tion [11,35]. An alternative name for galectin-3 is Mac-2 as it is
abundantly expressed by subsets of macrophages [42]. Galectin-3
can act in an autocrine or parcrine fashion to induce monocyte
migration [43] or alternative macrophage activation [7] and
regulate cytokine expression [44]. Therefore, as part of this process
is mediated by extracellular actions of galectin-3 [9], we propose
that MCP effects on inflammation in FA-nephropathy may in part
be mediated by galectin-3.
We also observed a small but highly significant reduction in
apoptosis with MCP in the later disease phase. This difference is
likely to be biologically important because Coles and colleagues [45]
previously demonstrated that small changes in measured apoptosis
in the kidney actually reflect larger overall changes in cell death due
to apoptotic cells being cleared so quickly. Galectin-3 and MCP
have different effects on apoptosis: galectin-3 has a BH1 domain of
BCL2 that can protect cells from apoptosis [46,47] and transfection
with the lectin makes T-cells resistant to this type of cell death [48];
MCP, in contrast, promotes apoptosis in angiosarcoma [49] and
prostate cancer cell lines [31]. This pro-apoptotic effect of MCP is
formulation-dependent, however, because alterations in pH and
heat-treatment (as we used here to prepare the MCP) can abrogate
these pro-apoptotic effects [50]. We suspect that our observed
reduction in apoptosis is not directly related to MCP actions on
galectin-3 but simply reflects the reduction in disease severity with
the modified pectin leading to less remodelling being required; in
this case, decreased early proliferation might generate less
‘unwanted’ cells that need to be deleted by apoptosis later.
In conclusion, our data indicates that MCP is protective in
experimental nephropathy through modulation of proliferation,
apoptosis, fibrosis and inflammation. However, there are two
caveats that need to be considered when interpreting this study.
Firstly, it is possible that MCP affects other molecular pathways
other than galectin-3 in FA nephropathy which need to be
investigated further. Secondly, we need to exert caution when
interpreting the effect of MCP on galectin-3 levels as these
measurements do not account for the bioavailability of the lectin
which may be altered. Nevertheless, this study does identify a new
potential therapy for acute kidney injury and further experiments
are warranted to examine effects of different doses of MCP, timing
of treatment and roles in other renal diseases.
Figure 7. Renal gene expression of fibrotic genes and cytokines. Quantitative RT-PCR for renal a-SMA (A), collagen I (B), collagen III (C),
fibronectin (D), TGFb-1 (E), MCP-1 (F), IL-1b (G), IL-6 (H) and TNF-a (I) on kidney RNA from animals in Group I (water throughout, NaHCO3 injection),
Group II (water throughout, FA injection) and Group III (MCP throughout and FA injection), two weeks after FA administration (n = 4 in Group I, 6 in
Group II and 7 in Group III). All genes were significantly upregulated in FA nephropathy compared to sham controls, but this was attenuated when
MCP was provided in the drinking water, except for collagen III, MCP-1 and IL-6. ** indicates p,0.01 while * indicates p,0.05.
doi:10.1371/journal.pone.0018683.g007
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